Alger

Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.

Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.

Redwood Investments, LLC is an employee-owned investment manager based in Newton, Massachusetts, founded in 2004. The firm primarily serves high net worth individuals, as well as institutional clients, including investment companies, pension plans, charitable organizations, and corporations. Redwood specializes in managing client-focused equity portfolios across global public markets, investing in a diverse range of growth, blend, and value stocks from small-cap, mid-cap, and large-cap companies. Its investment strategy involves a combination of quantitative and fundamental analysis, employing a bottom-up stock picking approach. The firm also offers Sustainable Investing strategies that incorporate environmental, social, and corporate governance factors. Redwood's experienced portfolio management team is dedicated to delivering superior investment performance and attentive client service.

Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.

Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.

Weatherbie Capital, LLC is an employee-owned investment manager based in Boston, Massachusetts, founded in December 1995 by Matthew Weatherbie. The firm specializes in managing equity portfolios and mutual funds, focusing primarily on growth stocks of small- and mid-cap companies in the United States. Weatherbie Capital employs a fundamental analysis and bottom-up research approach to investment, allowing it to identify and invest in attractive companies poised for growth. The firm serves a diverse clientele, including individuals, pension plans, charitable organizations, corporations, family offices, and government entities. As of 2017, Weatherbie Capital operates as a wholly owned subsidiary of Alger Associates Inc., continuing to uphold a strong track record of performance in its investment strategies.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. The company specializes in developing novel small-molecule antiviral therapeutics through its innovative drug discovery platform, which utilizes cell-free protein synthesizing systems. This platform enables the identification of small molecule drugs that may be overlooked by traditional pharmaceutical screening methods. Prosetta Biosciences is engaged in collaborative efforts with both commercial and non-profit partners to advance compounds targeting a variety of human diseases, including oncology, neurodegenerative disorders, and infectious diseases. The company's focus on modulating the assembly of multi-protein complexes within cells positions it as a significant player in the biopharmaceutical sector.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company based in Lehi, Utah, focused on discovering and developing novel therapeutics for cancer and other serious diseases. Founded in 2011, the company has several product candidates, including TP-0413, which regulates serum iron levels in patients with chronic inflammatory diseases like cancer and rheumatoid arthritis; TP-0903, a dual-targeted agent that inhibits pathways critical for pancreatic cancer cell growth; and TP-3654, a PIM inhibitor that helps ensure tumor cells respond to normal apoptosis signals, showing promise in treating prostate cancer and acute myeloid leukemia. Additionally, Tolero is developing TP-0829 for B-cell lymphomas and TP-0227 for endometrial carcinomas. The company's innovative approach aims to expedite drug development timelines and reduce costs compared to traditional methods, ultimately improving patient outcomes.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company based in Lehi, Utah, focused on discovering and developing novel therapeutics for cancer and other serious diseases. Founded in 2011, the company has several product candidates, including TP-0413, which regulates serum iron levels in patients with chronic inflammatory diseases like cancer and rheumatoid arthritis; TP-0903, a dual-targeted agent that inhibits pathways critical for pancreatic cancer cell growth; and TP-3654, a PIM inhibitor that helps ensure tumor cells respond to normal apoptosis signals, showing promise in treating prostate cancer and acute myeloid leukemia. Additionally, Tolero is developing TP-0829 for B-cell lymphomas and TP-0227 for endometrial carcinomas. The company's innovative approach aims to expedite drug development timelines and reduce costs compared to traditional methods, ultimately improving patient outcomes.

ChoiceStream is a programmatic advertising partner that specializes in managing cross-device branding and direct response campaigns for brand and agency clients. The company oversees all phases of a campaign, from pre-launch planning to completion, ensuring efficiency and effectiveness in reaching target audiences. By utilizing proprietary, poll-based data tailored to each client's needs, ChoiceStream creates custom, targetable audiences and optimizes campaign results in real-time. The firm employs advanced machine-learning algorithms and a team of industry experts to provide unique audience insights throughout each campaign. This combination of innovative technology and personalized service contributes to an impressive client retention rate, significantly surpassing the industry average.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.